Related Articles
Cilta-cel May Offer Another Path in Previously Treated Multiple Myeloma
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
ASH-EHA Translational Research Training in Hematology
ASH-EHA Translational Research Training in Hematology is a unique, year-long training and mentoring program focused on helping junior researchers build successful careers in hematologic translational…
ChatGPT Displays Potential for Genetic Counseling in Gynecologic Oncology
Jharna M. Patel, MD, discusses the utility of ChatGPT in genetic counseling for patients with gynecologic cancers.
Case Study: AML diagnosis, classification, risk-stratification and treatment
Sanam Loghavi and Naval Daver discuss the current approach to the diagnosis and classification, risk-stratification and treatment options for newly diagnosed AML in the context…
Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial
The benefit of early palliative care in a resource-limited setting is not well understood. This study examined whether early palliative care could improve
Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC
Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.
Board of Trustees
Overseeing the running of all aspects of the Society’s work, our Trustees are clinical experts with many years’ experience of working across all aspects of…
Mesenchymal stem cells as therapeutic vehicles for glioma
Cancer Gene Therapy – Mesenchymal stem cells as therapeutic vehicles for glioma
Low dose azacitidine + venetoclax as maintenance therapy for patients with AML in remission
Here, we summarize a phase II study investigating the safety and efficacy of low-dose azacitidine + venetoclax as maintenance therapy in patients with acute myeloid…